Waltham, Mass.-based Corvidia Therapeutics, a clinical-stage company focused on the research and development of transformative therapies for cardio-renal diseases, was founded in 2015. Its lead candidate ziltivekimab was being developed to reduce the risk of major adverse cardiovascular events in chronic kidney disease (CKD) patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation.  As such, Corvidia began preparing for its next significant financing and clinical milestones, wanting to leverage these events to raise the company’s profile with key stakeholders.

McDougall Communications partnered with Corvidia to develop a comprehensive plan that incorporated strategic messaging to clearly and concisely convey the company’s business strategy, lead asset and pipeline, disease state focus, and the proven track record of its executive leadership team. Over the course of two years, we executed the strategy and supported the company as it announced Series B financing, the appointment of a pharmaceutical industry leader as its new CEO, Phase 2b clinical study results, and clinical society and financial meetings such as the American Heart Association and J.P. Morgan Healthcare conferences. In the process, the visibility and reputation of the company grew substantially.

In 2020, Corvidia was acquired by Novo Nordisk for $725 million USD with total payments of up to $2.1 billion upon the achievement of certain regulatory and sales milestones—one of the most prominent transactions of the year. McDougall Communications continued to support Corvidia throughout this significant period, working closely with the global communications team at Novo Nordisk to ensure a smooth transition for the organizations, their investors, employees, and study partners.